VIDEX EC
LOE ApproachingNDAORALCAPSULE, DELAYED REL PELLETSPriority Review
Approved
Oct 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIDEX EC is an oral delayed-release capsule approved in 2000 for treatment of HIV infection. The product is a nucleoside reverse transcriptase inhibitor (NRTI) delivered via small-molecule formulation. It represents a foundational antiretroviral therapy class used in combination regimens.
LOE Approaching
Declining
Contracting portfolio presence with moderate competitive pressure (30/100) signals downsizing team focus and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect product maturity and declining commercial investment. Roles are concentrated in transition management, payer/prescriber relations, and compliance as the brand navigates LOE and potential discontinuation planning.
Brand ManagerMedical Science Liaison
Worked on VIDEX EC at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.